Incretin-Based Therapies: Revisiting Their Mode of Action

Endocrinology. 2017 Jun 1;158(6):1560-1563. doi: 10.1210/en.2017-00252.

Authors

Brian T Layden^{1

2}, Barton Wicksteed¹, Franck Mauvais-Jarvis³

Affiliations

¹ Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago, Chicago, Illinois 60612.
² Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois 60612.
³ Diabetes Research and Gender Medicine Laboratory, Section of Endocrinology and Metabolism, Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana 70112.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Comment

MeSH terms

Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors*
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents
Incretins*

Substances

Dipeptidyl-Peptidase IV Inhibitors
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Incretins
Glucagon-Like Peptide 1

Grants and funding